Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045

08:01 EDT 30 Apr 2019 | Businesswire
This article has expired, however you can still download the PDF.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the U.S. Food and...

Other Sources for this Article

Charles Liles

Media Contact
Jason I. Spark
Canale Communications


More From BioPortfolio on "Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045"

Quick Search

Relevant Topics

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...